Back

Incidence and risk factors for development of left ventricular hypertrophy in Fabry disease

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Anderson-Fabry disease: what is in store? Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Emanuele Monda

University of Campania Luigi Vanvitell, Naples (Italy)

6 More presentations in this session

Presentation thumbnail
Artificial intelligence (AI)-enhanced electrocardiography: a machine-learning model for differential diagnosis between hypertrophic cardiomyopathy, cardiac amyloidosis and Anderson-Fabry disease
Doctor I. Ruotolo (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Development and validation of a smartphone based app to guide the differential diagnosis in patients with primary left ventricular hypertrophy: the Thick Heart App
Doctor N. Maurizi (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Anderson-Fabry disease patients with anatomical heart hypertrophy express a higher degree of electrocardiographic hypertrophy compared to hypertrophic cardiomyopathy patients
Doctor F. Di Nicola (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Prognostic role of ECG patterns in Anderson Fabry disease.
Doctor S. Serratore (Catanzaro, IT)
Abstract Slides Video
Presentation thumbnail
Changes in peak oxygen consumption on excercise and cardiomyopathy disease stage in Fabry disease
Doctor A. Roy (Birmingham, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Anderson-Fabry disease: what is in store?

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Screening for Anderson-Fabry Disease in patients with left ventricular hypertrophy and disease-related red flags
thumbnail
Congress Presentation
Cardiovascular events in patients with Fabry disease: data froma multicentric nationwide study
thumbnail
Congress Presentation
Apical hypertrophic cardiomyopathy: could it be Fabry?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources